| 2024 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer
| ESMO OPEN |
| 2024 | Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06)
| BMC CANCER |
| 2024 | First-in-Human Phase 1 Study of a B Cell- and Monocyte-Based Immunotherapeutic Vaccine Against HER2-Positive Advanced Gastric Cancer
| CANCER RESEARCH AND TREATMENT |
| 2024 | Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study | JOURNAL OF CLINICAL ONCOLOGY |
| 2024 | Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib/II study | GASTRIC CANCER |
| 2024 | Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: a phase II trial
| NATURE COMMUNICATIONS |
| 2023 | Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial | LANCET |
| 2023 | Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
| SCIENTIFIC REPORTS |
| 2023 | Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial | LANCET ONCOLOGY |
| 2023 | Prior antibiotic administration disrupts anti-PD-1 responses in advanced gastric cancer by altering the gut microbiome and systemic immune response
| CELL REPORTS MEDICINE |
| 2023 | Impact of Coronavirus Disease 2019 on Gastric Cancer Diagnosis and Stage: A Single-Institute Study in South Korea
| JOURNAL OF GASTRIC CANCER |
| 2023 | Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
| MOLECULAR CANCER THERAPEUTICS |
| 2023 | Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial | INTERNATIONAL JOURNAL OF CANCER |
| 2023 | Monitoring the Outcomes of Systemic Chemotherapy Including Immune Checkpoint Inhibitor for HER2-Positive Metastatic Gastric Cancer by Liquid Biopsy
| YONSEI MEDICAL JOURNAL |
| 2023 | Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
| FRONTIERS IN ONCOLOGY |
| 2023 | Clinical relevance of clonal hematopoiesis and its interference in cell-free DNA profiling of patients with gastric cancer | CLINICAL CHEMISTRY AND LABORATORY MEDICINE |
| 2023 | Immunogenicity and Safety of Vaccines against Coronavirus Disease in Actively Treated Patients with Solid Tumors: A Prospective Cohort Study
| CANCER RESEARCH AND TREATMENT |
| 2023 | Care Needs of Adolescents and Young Adults with Cancer Undergoing Active Treatment in South Korea: A Mixed Methods Study | JOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY |
| 2023 | Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Advanced Gastric or Gastroesophageal Junction Cancer | JOURNAL OF CLINICAL ONCOLOGY |
| 2023 | Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform
| ONCOLOGIST |
| 2023 | PBRM1-deficient PBAF complexes target aberrant genomic loci to activate the NF-κB pathway in clear cell renal cell carcinoma | NATURE CELL BIOLOGY |
| 2023 | High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma
| JHEP REPORTS |
| 2023 | Status of Using Complementary and Alternative Medicine among Patients with Cancer in Korea: an Online Survey of Online Cancer Support Groups (KCSG PC21-20)
| CANCER RESEARCH AND TREATMENT |
| 2023 | VP1-2023: Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study | ANNALS OF ONCOLOGY |
| 2023 | Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study | LANCET ONCOLOGY |
| 2023 | Risk factors for delirium among patients with advanced cancer in palliative care: a multicenter, patient-based registry cohort in South Korea
| EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES |
| 2023 | Silmitasertib plus gemcitabine and cisplatin first-line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study | HEPATOLOGY |
| 2023 | INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)
| BMC CANCER |
| 2023 | Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer
| NEW ENGLAND JOURNAL OF MEDICINE |
| 2023 | Outcomes of an Acute Palliative Care Unit at a Comprehensive Cancer Center in Korea
| PALLIATIVE MEDICINE REPORTS |
| 2023 | Breakthroughs in the Systemic Treatment of HER2-Positive Advanced/Metastatic Gastric Cancer: From Singlet Chemotherapy to Triple Combination | JOURNAL OF GASTRIC CANCER |
| 2023 | Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma
| ONCOLOGIST |
| 2022 | Enhanced supportive care for advanced cancer patients: study protocol for a randomized controlled trial
| BMC NURSING |
| 2022 | Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study | LANCET ONCOLOGY |
| 2022 | Analytical and Clinical Validation of Cell-Free Circulating Tumor DNA Assay for the Estimation of Tumor Mutational Burden | CLINICAL CHEMISTRY |
| 2022 | Efficacy and safety of pembrolizumab (pembro) monotherapy in East Asian patients (pts) with urothelial carcinoma (UC) in KEYNOTE-045 or KEYNOTE-052 | ANNALS OF ONCOLOGY |
| 2022 | Understanding the Social Mechanism of Cancer Misinformation Spread on YouTube and Lessons Learned: Infodemiological Study
| JOURNAL OF MEDICAL INTERNET RESEARCH |
| 2022 | A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer
| NATURE COMMUNICATIONS |
| 2022 | First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors
| INVESTIGATIONAL NEW DRUGS |
| 2022 | Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial
| EUROPEAN UROLOGY |
| 2022 | Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer | EUROPEAN JOURNAL OF CANCER |
| 2022 | Probe-Based Confocal Laser Endomicroscopy versus White-Light Endoscopy with Narrow-Band Imaging for Predicting and Collecting Residual Cancer Tissue in Patients with Gastric Cancer Receiving Chemotherapy
| CANCERS |
| 2022 | The UGT1A9*22 genotype identifies a high-risk group for irinotecan toxicity among gastric cancer patients
| Genomics & Informatics |
| 2022 | Phase II Clinical Trial of Eribulin-Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma | CLINICAL CANCER RESEARCH |
| 2022 | PD-L1 expression and overall survival in Asian and western patients with gastric cancer | FUTURE ONCOLOGY |
| 2022 | Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition
| GUT |
| 2022 | Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study | LANCET ONCOLOGY |
| 2022 | Self-efficacy for coping with cancer and quality of life in advanced gastric cancer patients | EUROPEAN JOURNAL OF ONCOLOGY NURSING |
| 2022 | Fear of cancer recurrence and its predictors and outcomes among cancer survivors: A descriptive correlational study | EUROPEAN JOURNAL OF ONCOLOGY NURSING |
| 2022 | Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16) | GASTRIC CANCER |
http://orcid.org/0000-0002-2512-4531
(7006023235)
